Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: rjee who wrote (49067)	6/4/1999 7:15:00 PM
From: Jane4IceCream	Read Replies (3) \| Respond to of 90042

I am not involved in the biotech industry, but have several "contacts" in the industry including an employee at Immune Resources here in North San Diego County who knows about the major cancer treatments currently on the market and those in the pipeline. She is very well versed in what treatments and products other cancer treatment bio like IMCL and IMNX and ICOS have in their pipelines. Living here surrounded by several biotech companies also allows me to read alot of news in the Tribune about ongoing clinical testing and product updates. I have invested in and traded in a few biotechs and pharmaceuticals in the recent past and either you play the stock for expected trial results, as a "story" or in the case of some if they have major agreements with major companies for partnerships in research, production, and distribution/marketing. I hold IMCL long term because of the explosive possibilities of their C225 cancer treatment currently in Phase III trials with most astonishing results. Check them out and also check out the chart on this stock. I have traded IMNX a couple times because of their Embrel product but it is an expensive and very volatile issue so be careful if considering. I have ICOS in my IRA since $15. Love IMNR at this price level. They have a product called Remune that has had favourable results so far (head and neck cancers). Etc, etc. Jane